TrialAnnals of oncology : official journal of the European Society for Medical Oncology2014

A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

C H Chung et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.